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Abstract
Maraviroc (MVC) gels are effective at protecting rhesus macaques from vaginal SHIV transmission, but breakthrough
infections can occur. To determine the effects of a vaginal MVC gel on infecting SHIV populations in a macaque model, we
analyzed plasma samples from three rhesus macaques that received a MVC vaginal gel (day 0) but became infected after
high-dose SHIV-162P3 vaginal challenge. Two infected macaques that received a placebo gel served as controls. The
infecting SHIV-162P3 stock had an overall mean genetic distance of 0.29460.027%; limited entropy changes were noted
across the envelope (gp160). No envelope mutations were observed consistently in viruses isolated from infected macaques
at days 14–21, the time of first detectable viremia, nor selected at later time points, days 42–70. No statistically significant
differences in MVC susceptibilities were observed between the SHIV inoculum (50% inhibitory concentration [IC50] 1.87 nM)
and virus isolated from the three MVC-treated macaques (MVC IC50 1.18 nM, 1.69 nM, and 1.53 nM, respectively).
Highlighter plot analyses suggested that infection was established in each MVC-treated animal by one founder virus
genotype. The expected Poisson distribution of pairwise Hamming Distance frequency counts was observed and a
phylogenetic analysis did not identify infections with distinct lineages from the challenge stock. These data suggest that
breakthrough infections most likely result from incomplete viral inhibition and not the selection of MVC-resistant variants.
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Introduction
Vaginal intercourse is now the most common mode of HIV-1
transmission worldwide [1,2]. Microbicide gels containing anti-
retroviral compounds (ARVs) applied vaginally constitute one
plausible intervention strategy [3,4]. Proof-of-concept for this
method of prophylaxis has been obtained in animal models using
various ARVs, and a tenofovir-based microbicide gel has shown
protective efficacy in women [5–10]. However, breakthrough
infections can occur in animals and humans for one of several
reasons, including non-adherence (in humans), the presumed
inadequate delivery of the active drug to its site of action, and the
presence of viral variants resistant to the ARV. Tenofovir-related
resistance mutations were not detected by standard clinical HIV-1
genotype testing on plasma viral isolates from women who became
HIV-infected while using a tenofovir vaginal gel [9]. Nonetheless,
it remains relevant to understand what selective effects a vaginal
microbicide prophylaxis regimen may have on the infecting
viral quasispecies because of general concerns about the spread
of drug-resistant variants [3,4,11,12]. Naturally occurring CCR5
antagonist-insensitive virus variants have been reported prior to
drug challenge [13–15].
HIV transmission most commonly involves viruses that use the
CCR5 coreceptor for entry into cells [16,17]. Accordingly, specific
inhibitors that bind to CCR5 can prevent infections of rhesus
macaques with CCR5-using viruses, such as SHIV-162P3 [5,6].
Maraviroc (MVC) is the only CCR5 antagonist approved for
treatment of HIV-1 infection [18,19]. A maraviroc (MVC) vaginal
microbicide protected macaques in a dose- and time-dependent
manner from high-dose SHIV-162P3 vaginal challenge [10].
However, some breakthrough infections did occur even when
MVC was applied at high concentrations in the protective range
(gel concentrations of 0.6–5.8 mM) [10]. One explanation is that
an insufficient amount of MVC was present in the right place at
the right time (pharmacological failure), a second is that some
viruses present in the challenge virus stock were partially resistant
to MVC and were selected for by the gel (resistance failure).
We note that another CCR5 inhibitor, PSC-RANTES, was
reported to select for a resistant SHIV-162P3 variant when
applied vaginally to macaques, although this conclusion has since
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been questioned [20,21]. Here, we investigated whether SHIV-
162P3 variants infecting macaques in the presence of a MVC
vaginal gel have any genetic and phenotypic characteristics
indicative of resistant viruses.
Results
To characterize the SHIV-162P3 inoculum, we performed a
standard clonal analysis of 42 independent full-length env clones
isolated from the infecting stock. Standard PCR and cloning
provided similar measures of population diversity when compared
directly to single genome sequencing; sampling bias occurred with
either method [22]. A phylogenetic analysis was performed to
graphically represent SHIV-162P3 diversity and entropy calcula-
tions quantified sequence variation by nucleotide position (Fig. 1).
Minor sequence differences were present throughout gp160,
although several positions in gp120 and gp41 were invariant. An
entropy of approximately 0.1 corresponds to one nucleotide
difference at a given position in one sequence amongst all 42
SHIV sequences. A diversity estimate of the SHIV-162P3 stock
demonstrated an overall mean genetic distance of 0.29460.027%
(standard error), consistent with prior reports [23,24]. We
compared full-length env sequences from SHIV-162P3 stock
isolated by standard cloning with previously reported sequences
generated by single genome amplification (Fig. 2) [25]. Sequences
obtained by either method generated a SHIV-162P3 consensus
sequence that was identical at all nucleotide positions across the
length of gp160.
To investigate the characteristics of infecting SHIV populations,
we studied viral isolates from five rhesus macaques: Mac46,
Mac73, and Mac80 received a MVC-containing vaginal gel and
macaques CR02 and L375 received a placebo vaginal gel and
served as a comparator group. Two time points were assessed
for each animal: T1, the time of first detectable plasma viremia
(day 14 or 21), and T2, a later time point (days 56–70). Plasma
SHIV RNA levels were quantified over the study duration
(Table 1). The env genotypic changes that occurred in infected
macaques were studied by isolating and sequencing multiple
independent full-length plasma-derived env clones. A clonal full-
length env sequence analysis demonstrated that, compared to the
SHIV-162P3 inoculum, nearly homogeneous wild-type sequence
populations were present in the V3 region of gp120 and the gp41
fusion peptide of Mac46, Mac73, and Mac80 (Fig. 3). These two
envelope regions have been associated with CCR5 inhibitor
resistance [26–29]. Non-synonymous mutations were identified in
T1 plasma-derived full-length env from all animals; they resulted in
a maximum of three amino acid changes per clone, relative to the
consensus SHIV162-P3 sequence (data not shown). No consistent
amino acid changes in gp160 sequence outside V3 or the gp41
fusion peptide were noted in any of the five infected macaques.
To determine MVC susceptibility, we generated pseudoviruses
derived from the most prevalent full-length env clone present in T1
plasma from Mac46, Mac73, Mac80, and CR02 [30,31]. Two
additional clones from animals Mac46 and Mac80 that contained
sporadic gp160 mutations were also tested. Pseudoviruses that
incorporated population-derived env from SHIV-162P3 stock and
T1 CR02 were used to determine comparator MVC susceptibil-
ities. All the env-pseudotype viruses were fully inhibited by MVC,
with maximal percent inhibition (MPI) values of 99–100% (Fig. 4).
The observed IC50 values for the SHIV-162P3 stock and T1 CR02
control virus were 1.87 nM (95% confidence intervals [CI], 1.45–
2.41) and 1.30 nM (0.94–1.80), respectively. Viruses that incor-
porated the dominant T1 Mac46, Mac73, and Mac 80 env had
MVC IC50s of 1.18 nM (0.54–2.58), 1.69 nM (0.76–3.76), and
1.53 nM (0.56–4.2), respectively. The minority Mac46-20 and
Mac80-30 clones demonstrated MVC IC50s of 0.89 nM (0.49–
1.61) and 1.10 nM (0.71–1.69). No statistically significant
differences in MVC IC50s or MPIs were observed between any
tested viruses. Hence SHIV infection was established in each
macaque by CCR5-using virus; MVC susceptibilities did not differ
from the infecting SHIV stock or a placebo-treated animal.
We next investigated the effect of a MVC vaginal gel on the
number of SHIV viruses that established the initial infections
(Fig. 5) [32]. The phylogenetic estimates, supported by highlighter
plot analyses, suggest that SHIV-162P3 infections in Mac46,
Mac73, and Mac80 were established by a single, or a few very
closely related, viral genotype(s). We observed the expected
Poisson distribution of pairwise Hamming Distance frequency
counts, consistent with transmission of a single viral variant in each
animal [33].
Although the MVC gel did not affect the number of founder
viruses or their susceptibility to MVC, it remained possible that it
Figure 1. The diversity of the infecting SHIV-162P3 inoculum. (A) A maximum likelihood tree constructed with 42 independent full-length
clones isolated from the infecting SHIV-162P3 inoculum. An unrooted tree layout is displayed. The horizontal scale bar represents genetic distance.
(B) Entropy plot of inoculum diversity as a function of nucleotide position.
doi:10.1371/journal.pone.0028047.g001
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could have selected for particular transmitted lineages of the
SHIV-162P3 stock. To evaluate the genetic relatedness of the
infecting viruses in Mac46, Mac73 and Mac80, we constructed a
Neighbor Joining tree, rooted on the SHIV-162P3 consensus
sequence, that included full-length env sequences isolated at T2
(day 42) from the two control macaques, L375 and CR02, T1
sequences from CR02, and the SHIV-162P3 stock clones (Fig. 6).
T1 sequences from Mac46, Mac73, and Mac80 shared a
monophyletic cluster with clonal sequences from the SHIV-
162P3 challenge stock, macaques CR02 and L375, and the
derived SHIV consensus sequence. Some T2 env sequences
diverged from those obtained at T1. T2 sequences from Mac46
and Mac80 each formed distinct clusters that did not mix with
ones from other macaques; a subset of Mac80 T2 sequences were
placed in the shared monophyletic lineage. Evolution of Mac73 T2
sequences from T1 sequences was not observed. Overall, the
evolutionary relationships between the SHIV-162P3 stock and env
sequences isolated over 70 days of observation did not appreciably
differ between the MVC-exposed and control macaques.
Discussion
We investigated the genotypic and phenotypic properties of
SHIV-162P3 macaque infection in the presence of a MVC-
containing vaginal gel and found that infecting viral populations
closely resembled the stock inoculum. The above analyses imply
that the presence of an MVC-based vaginal microbicide gel did
not drive the selective transmission of MVC-insensitive variants to
SHIV-162P3-challenged macaques. That is an important finding,
given the uncertainty that surrounds the identification of a
Figure 2. The relationship between SHIV-162P3 stock full-length env obtained by standard cloning and single genome
amplification. (A) An unrooted maximum likelihood tree constructed with standard clones and 17 previously reported sequences generated by
single genome amplification. Blue circles, SGA clones; Yellow circles; standard clones. The horizontal bar represents genetic distance. (B) Highlighter
plot indicates the gp160 nucleotide variation between clones. Clones are numbered sequentially; SGA clones are depicted with ‘‘sga’’ after the clone
number. Adenine, green; Cytosine, aqua; Thymine, red; Guanine, orange. Grey bars indicate missing sequence.
doi:10.1371/journal.pone.0028047.g002
Table 1. SHIV Plasma Viral Loads in MVC-treated and comparator macaques.
SHIV RNA copies/mL on Day:
Animal Gel Treatment 0 7 14 21 42 56 70
CR02 Control - ,125 4,616,200 191,166 56,905 221 ,125
L375 Control ,125 ,125 2,357,700 94,787 10,540 - 3,809
Mac46 5.8 mM MVC ,165 ,165 1,861,200 2,875,900 22,205 25,657 5,443
Mac73 2.9 mM MVC - ,165 ,165 464,078 5,691 349 3,995
Mac80 0.6 mm MVC - ,165 80,116 5,609,100 143,598 19,980 3,739
doi:10.1371/journal.pone.0028047.t001
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transmitted SHIV-162P3 variant with apparent resistance to
vaginally administered PSC-RANTES [20,21]. The infections in
the three MVC recipients and the control animals were established
by a similarly limited number of variants, just as was seen in
untreated macaques challenged intra-vaginally with SIVmac251,
and in sexually infected women [25,34–39]. This finding is
particularly noteworthy given that the animals in this and another
recent study were treated with Depo-Provera to thin the vaginal
epithelium and facilitate vaginal transmission [25]. The small
number of HIV-1 variants that established infection in women
using a tenofovir-containing vaginal microbicide was also not
significantly different from control [40].
The relatively small number of sequences used to determine
founder virus lineage is a limitation of this analysis. Although 13–
15 SIV clones were sequenced from each macaque, there is at
best a 70–80% probability by Poisson calculations that we did not
miss a lineage present at 10% or less of the total transmitted viral
population. Reassuringly, the conclusions of founder virus
analyses have been confirmed when re-calculated with more
comprehensive deep sequencing data sets [41,42]. Within these
limitations, we found no evidence that a MVC-based microbicide
gel affects the types of genetic variants that ultimately establish
infection, and we also showed that infections in vaginally-
challenged macaques are established by one or a very few
variants. Given the small number of infected animals we had
available for study, animal and human participants in future trials
of microbicide candidates should be studied to assess the
generalizability of our findings.
Figure 3. Alignment of gp120 V3 and gp41 fusion peptide sequences obtained pre-challenge and from post-challenge time points
1 and 2. Independent clonal sequences isolated from three MVC-exposed, SHIV-162P3 infected macaques are shown. The pre-challenge sequences
are the same for each macaque as they were derived from the SHIV-162P3 challenge stock. Predicted amino acid differences are shown and
similarities indicated with dashes. The number of independent clones with the identical sequence is indicated to the left of each sequence. (A) Mac46,
(B) Mac73, (C) Mac80. FP, fusion peptide.
doi:10.1371/journal.pone.0028047.g003
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An additional caveat is that the quasispecies diversity of a
SHIV-162P3 challenge stock may not adequately mimic the
diversity involved in sexual exposure to HIV-1. Intra-host HIV-1
envelope and V3 loop sequence diversity can range from 4–10%, a
factor of 10 greater than the genetic distances observed in infecting
SHIV-162P3 inocula [43,44]. Under these circumstances, there
could be subtle selective effects of a microbicide (MVC or other)
on the infecting viral phenotype that we would not have detected
in the present study. As an extreme example, a CCR5 inhibitor
like MVC would inevitably not interfere with the transmissibility
of CXCR4-using HIV-1 variants present in semen.
We could not evaluate whether MVC-resistant SHIV variants
were locally selected under drug pressure and remained
compartmentalized in the lower female genital tract. Pharmaco-
kinetic studies have shown that plasma concentrations of MVC
peak 2 hours after intravaginal administration of a 6 mM MVC-
containing HEC gel at approximately 4 nM, a concentration at
least twice that of the observed IC50s of viral isolates from this
study [45]. MVC levels quickly decay thereafter and are
undetectable in plasma 24 hours after gel administration. Plasma
viremia is not detectable until days later, raising the possibility that
the drug concentrations are not high or sustained enough outside
the genital mucosa to select for viral resistance [10,46].
We believe that the explanation for why some animals became
infected despite the presence of a gel containing millimolar
concentrations of MVC most likely is rooted in the pharmacology
of inhibitor delivery (we note that 2 of the animals did receive sub-
optimal MVC concentrations). Leakage of the gel and its active
ingredient and/or a failure of the inhibitor to reach and occupy all
the CCR5 targets in the lower female genital tract are probably
responsible. While no protection will ever be 100% effective, the
value of vaginal microbicides to prevent HIV-1 infection is now
clear [9]. The development of better delivery systems and the use
of ARV combinations can only increase the chances that a
microbicide will eventually be of substantial value to populations
of women at risk for heterosexual HIV-1 infection.
Materials and Methods
Ethics Statement
The Institutional Animal Care and Use Committee (IACUC) of
Tulane University reviewed and approved all macaque procedures
described (protocol permit number 3501). This study was carried out
in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health (NIH) and with the recommendations of the Weatherall
report, ‘‘The use of non-human primates in research’’. All procedures
were performed under anesthesia using ketamine, and all efforts were
made to minimize suffering, improve housing conditions, and to
provide enrichment opportunities (e.g., objects to manipulate in cage,
varied food supplements, foraging and task-oriented feeding methods,
interaction with caregivers and research staff).
Macaque samples
We studied viral isolates from five rhesus macaques. Three
animals, designated macaque 46 (Mac46), macaque 73 (Mac73), and
Figure 4. Maraviroc susceptibilities of pseudoviruses with full-length T1 envelopes. In each graph, the percentages of inhibition relative
to the extent of virus replication in the no-MVC control at various MVC concentrations are shown. The MVC susceptibilities of the following clones are
shown: (A) Mac46–19, the most prevalent Mac46 day 14 env clone, (B) Mac463–20, a minority day 14 Mac46 env clone, (C) Mac73–34, the most
prevalent day 21 Mac73 env clone, (D) Mac803–28, the most prevalent day 14 Mac80 env clone, (E) Mac803–30, a minority day 14 Mac80 env clone,
(F) SHIV stock and CR02, the most prevalent env clones from the pre-infection SHIV-162P3 stock and day 14 control macaque CR02, respectively. Error
bars represent the standard errors of the means of results from at least two experiments, each performed in triplicate. Nonlinear regression with a
variable slope was used to estimate a fitted curve. MVC, maraviroc.
doi:10.1371/journal.pone.0028047.g004
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macaque 80 (Mac80), received hydroxylethyl cellulose (HEC)-based
vaginal gels containing 5.8 mM, 1.9 mM, and 0.6 mM of MVC,
respectively, 30 min before an intra-vaginal challenge with 500 50%
Tissue Culture Infectious Doses (TCID50) of SHIV162-P3, but
became infected. Two infected control macaques, L375 and CR02,
given an HEC placebo gel prior to SHIV-162P3 challenge, served as
sources of comparator sequences. Two plasma samples collected
from each macaque at an early time point (time 1, T1, days 14–21),
when viral RNA was first detected, and a later time point (time 2, T2,
days 42–70) after challenge were available for analysis.
Cells and cell culture
TZM-bl and U87-CD4-CCR5 cells were obtained from the NIH
AIDS Research and Reference Reagent Program (ARRRP). 293T
Figure 5. Neighbor-joining trees, Highlighter plots, and Hamming Distance frequency plots for independent T1 env clones. (A)
Mac46, (B) Mac73, (C) Mac80. Only near full-length sequences were used to construct NJ trees; fewer sequences are included than in Figure 1.
Highlighter plots indicate nucleotide variation from the consensus; a base mixture at a given position in the consensus sequence is indicated as a
variation in the highlighter plot, even if that base is present in the consensus mixture. The horizontal scale bars represent genetic distance. Adenine,
green; Cytosine, aqua; Thymine, red; Guanine, orange. Grey bars indicate missing sequence. Hamming Distance (HD) analyses removed APOBEC-
modified positions from all sequences; theoretical pairwise HD frequency counts are shown as a continuous red line. Numbers above histogram
columns denote the frequency observed for each HD.
doi:10.1371/journal.pone.0028047.g005
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cells were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). TZM-bl and 293T cell lines were
maintained in Dulbecco modified Eagle medium with L-glutamine
(DMEM, Gibco, Invitrogen) supplemented with 10% fetal bovine
serum (Invitrogen), 100 U/ml penicillin and 100 mg/mL strepto-
mycin (Cellgro, Mediatech) that was referred to as DMEM complete
(DMEM-C). U87-CD4-CCR5 cells were grown in DMEM-C plus
300 mg/mL of geneticin (G418, Sigma) and 1 mg/mL puromycin
(MP Biomedicals) to maintain CD4 and CCR5 coreceptor expre-
ssion. All cell cultures were maintained at 37uC and 5% CO2.
Maraviroc and susceptibility testing
Maraviroc was obtained from the NIH ARRRP. Clonal
susceptibility testing was performed as previously described
[28,47].
HIV-1 env cloning
Viral RNA was extracted from macaque plasma (QIAamp viral
RNA mini kit, Qiagen) and env amplicons encoding gp160 were
generated by nested PCR as described [28]. To minimize any
potential founder effect, four independent RT reactions and PCR
amplifications were performed and combined for each time point.
These purified amplicons were then ligated into a TOPO- TA
vector (Invitrogen) and electroporated into TOP10 cells. Sub-
clones were isolated and sequenced by conventional (Sanger)
methods as described [28]. Between 15 and 42 clones were
sequenced per time point. All sequences were edited, aligned, and
compiled with Geneious Pro version 5.4.6 [32]. Envelope
sequences could not be amplified from L375 T1 plasma aliquots
using multiple well-validated primer sets; this time point was
excluded from further analyses.
Figure 6. Phylogenetic analysis of T1 and T2 gp160 env sequences. Composite tree of 169 complete gp160 sequences that includes
independent sequences isolated from the infecting SHIV-162P3 challenge stock and MVC-exposed and control macaques. Black star, SHIV-162P3
consensus env sequence; open stars, clonal SHIV-162P3 isolates; orange diamonds, day 14 Mac80; light green circles, day 21 Mac73; light blue
squares, day 14 Mac46; red diamonds, day 70 Mac80; dark green circles, day 42 Mac73; dark blue squares, day 56 Mac46; grey triangles, day 14 control
macaque CR02; black triangles, day 42 CR02; inverted black triangles, day 42 control macaque L375. Numerals indicate posterior probabilities of node
support. The horizontal scale bar represents genetic distance.
doi:10.1371/journal.pone.0028047.g006
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Sequence and Evolutionary analysis
The mean pairwise distance of 42 full-length env clones isolated
from the SHIV-162P3 stock were calculated using MEGA5 [48].
The Shannon entropy at each position of the SHIV-162P3 stock
inoculum aligned gp160 sequence data set were calculated with
Entropy-One (www.hiv.lanl.gov/content/sequence/ENTROPY/
entropy_one.html). Full-length env sequences were aligned, inspect-
ed with the Highlighter tool (http://www.hiv.lanl.gov/content/
sequence/HIGHLIGHT/highlighter.html), and used to construct
consensus neighbor-joining phylogenetic trees of the T1 sequen-
ces. Poisson-Fitter was used to calculate Pairwise Hamming Dis-
tance frequency counts (http://www.hiv.lanl.gov/content/sequence/
POISSON_FITTER/poisson_fitter.html).
Full-length gp160 sequences isolated from the infecting SHIV-
162P3 stock, control macaques L375 and CR02, and MVC
vaginal gel-treated Mac46, Mac73, and Mac80 were included in
phylogenetic analyses of env evolution. A FindModel analysis
(www.hiv.lanl.gov/content/sequence/findmodel/findmodel.html)
selected the Tamura-Nei model as the most appropriate for
subsequent analyses [49]. Neighbor joining trees with a signifi-
cance cutoff of 70% and the SHIV-162P3 challenge virus consensus
env as an outgroup were constructed for gp160 sequences using
Geneious; trees were resampled in 1,000 bootstrapped replicates
[32]. An unrooted maximum likelihood tree of infecting clonal
SHIV-162P3 sequences was generated with the PhyML plug-in of
Geneious [50]. The ML tree was resampled in 1,000 bootstrapped
replicates and optimized for tree topology and branch length.
Virus construction
Recombinant virus that incorporated HIV-1 envelopes from
Mac46, Mac73, Mac80, CR02 and the SHIV-162P3 inoculum
were constructed by a modification of a previously described
method [30,31]. Briefly, the CMV promoter was amplified and
attached to a 265 base-pair segment of rev from pNL43 using
overlap PCR. A second overlap PCR was then performed to link
CMV-rev to the cloned or uncloned env amplicon of interest.
These CMV-rev-env amplicons were then co-transfected into
293T cells with an NL4-3 envelope-deleted vector [51].
To generate infectious virus, we transfected 293T cells with
CMV-rev-env amplicons together with the env-deleted NL4-3.
Briefly, 86106 293T cells were plated and cultured overnight at
37uC. On the day of transfection, culture media was double
washed with phosphate-buffered saline (PBS, Cellgro, Mediatech),
replaced by fresh phenol red-negative DMEM-C and warmed to
37uC. We used the Fugene 6 protocol (Roche Molecular
Biochemicals) to transfect cells as previously described [28,47].
Supernatants were collected 48 hours later, passed through a
0.45 mM filter, centrifuged at 72,000 g for 90 min at 4uC,
aliquoted and stored at 280uC until use. Viral titers were
determined by endpoint dilution as described.
Nucleotide sequence accession numbers
SHIV162-P3 env sequences were deposited in GenBank under
accession numbers JN979788-JN979955. SGA SHIV162-P3 env
sequences JN011407.1 - JN011423.1 were retrieved from
GenBank on October 14, 2011.
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